Pure Global
NCT02055586

FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents

A Pilot Study of FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
Case Comprehensive Cancer Center·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
fluorine F 18 fluorothymidine
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Case Comprehensive Cancer Center
Location
Cleveland, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 22, 2013
End date
Dec 27, 2017
Enrollment
10 participants
Primary outcome

Concordance analysis of standardized uptake values (SUVs) between the 2 baseline scans,Comparative Analysis of PET/MRI Images

Summary

This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission
 tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with
 metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic
 procedures, such as FLT-PET/MRI, may help measure a patient's response earlier during
 treatment.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02055586
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02055586 through Pure Global AI's free database. This phase not specified trial is sponsored by Case Comprehensive Cancer Center and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.